Overview

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
0
Participant gender:
All
Summary
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Criteria
Inclusion Criteria:

1. Signed written informed consent must be obtained and documented according to
International Conference on Harmonization (ICH)- Good Clinical Practice (GCP), the
local regulatory requirements, and permission to use private health information in
accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior
to study-specific screening procedures

2. A histologically or cytologically confirmed ovarian, breast, non-small cell lung,
melanoma, gastric/GEJ/esophageal or other type of advanced cancer that is metastatic,
unresectable, or recurrent and for which weekly paclitaxel is an acceptable
therapeutic option.

3. Patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer must
also meet the following criteria: a. Must be either platinum-resistant or
platinum-refractory according to the following definitions:(1)Platinum-resistant: a
response to platinum therapy followed by progression within 6 months after completing
therapy (2)Platinum-refractory: best response of stable disease or progression during
platinum therapy; b. Must have had prior systemic treatment with a taxane; c. Must
have received no more than 4 prior systemic cytotoxic regimens

4. Patients with melanoma must also meet the following criteria: a. If melanoma is BRAF
wild-type or has BRAF mutations that are not amenable to BRAF inhibitor therapy, and
the patient is a candidate for immunotherapy, must have received ipilimumab; b. If
melanoma is positive for the V600E or V600K BRAF mutation, must have received at least
one line of prior therapy with a BRAF-specific inhibitor; either alone or in
combination.

5. Patients with triple negative breast cancer (estrogen receptor-negative (ER-),
progesterone receptor-negative (PR-), and human epidermal growth factor receptor
2-negative (Her2-) must also meet the following criteria: a. Must have received at
least one prior chemotherapy regimen for locally advanced or metastatic disease; b.
Must have received prior taxane therapy.

6. Patients with NSCLC (adenocarcinoma, squamous, or adenosquamous histopathology) must
also meet the following criteria: a. Must have disease that is stage IIIB, not curable
by surgery or radiotherapy, or stage IV; b. Must have received at least one prior
chemotherapy regimen for locally advanced or metastatic disease; c. EGFR-positive or
ALK-positive patients must have received at least one line of EGFR-directed or
ALK-directed therapy, respectively; d. Must have received prior taxane therapy.

7. Patients with adenocarcinoma arising from the esophagus, gastroesophageal junction, or
stomach must also meet the following criteria: a. Must have received prior treatment
with a platinum/fluoropyrimidine-based therapy with or without an anthracycline in the
metastatic setting; or, in the adjuvant setting if recurrence occurred within 6 months
of completing systemic adjuvant treatment; b. Patients with HER2 positive tumors must
have had prior treatment with a Her2 inhibitor (e.g. trastuzumab or lapatinib); c.
Patients who have received prior taxane therapy may be enrolled.

8. Patients with thymic carcinoma must have received at least one prior systemic
chemotherapy regiment for metastatic, recurrent, locally advanced or otherwise
unresectable disease.

9. ≥ 18 years of age

10. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST
1.1, see Section 9)

11. Karnofsky performance Status ≥ 70% (Section 15)

12. Male or female patients of child-producing potential must agree to use contraception
or avoidance of pregnancy measures during the study and for 30 days after the last
BBI608 dose

13. Females of childbearing potential must have a negative serum pregnancy test

14. Aspartate transaminase (AST) and alanine transaminase (ALT) £1.5 × upper limit of
normal (ULN), or ≤ 2.5 × ULN with metastatic liver disease

15. Hemoglobin (Hgb) ≥ 10 g/dl

16. Total bilirubin £ 1.5 × ULN

17. Creatinine £ 1.5 ´ ULN or creatinine clearance > 60 mL/min/1.73 m2 for patients with
creatinine levels above institutional normal

18. Absolute neutrophil count ³ 1.5 x 109/L

19. Platelets ≥ 100 x 109/L

20. Life expectancy ≥ 3 months

Exclusion Criteria:

1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
within 7 days of first dose provided all treatment-related adverse events have
resolved or have been deemed irreversible, with the exception for a single dose
radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up
to 7 days before beginning the administration of BBI608.

2. Surgery within 4 weeks prior to first dose

3. Any known symptomatic brain metastases requiring steroids. Patients with treated brain
metastases must be stable for 4 weeks after completion of that treatment, with image
documentation required. Patients must have no clinical symptoms from brain metastases
and must be either off steroids or on a stable dose of steroids for at least 2 weeks
prior to protocol enrollment. Patients with known leptomeningeal metastases are
excluded, even if treated

4. Pregnant or breastfeeding

5. Significant gastrointestinal disorder(s), in the opinion of the Principal
Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small
intestine resection)

6. Unable or unwilling to swallow BBI608 capsules daily

7. Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, clinically significant non-healing or healing wounds, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant
pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled
infection or psychiatric illness/social situations that would limit compliance with
study requirements

8. Known severe hypersensitivity to paclitaxel

9. Abnormal ECGs (ie, QT prolongation - QTc > 480 msec, signs of cardiac enlargement or
hypertrophy, bundle branch block, signs of ischemia or necrosis and Wolff Parkinson
White patterns)